الفهرس 
gastrointestinal disorders
solid dispersionOnly 14 pages are availabe for public view
 |  | from | 229 |  |  |
| | | from | 229 | | |
Abstract
Sulindac is a NSAID, acetic acid derivative. It is useful in the treatment of acute and chronic inflammatory conditions by acting on enzymes cox-1 and cox-2, inhibiting prostaglandin (PG) synthesis. It is used for the treatment of rheumatoid arthritis, osteoarthritis, fever, inflammation, and as non narcotic reliever of mild to moderate pain of injury, menstrual cramps, arthritis and musculoskeletal pain. Sulindac was proved to cause significant gastrointestinal (GI) toxicity. Drug related upper GI events, such as dyspepsia or peptic ulcer and complications such as perforation or bleeding which requires hospitalizations for serious stomach or duodenum disorders. As gastrointestinal lesions are an important clinical problem associated with the use of sulindac. It is necessary to investigate the relationship between GI-lesions and drug formulation from an early stage of formulation study in order to design a product which doesn’t cause GI-lesions. Our research underlines the importance of minimizing the ulcerogenic effect of sulindac by either preventing its direct contact with the GIT by coating with enteric polymers or improving its solubility by using other protective polymers.